Small molecule shows promise in treating temporal lobe epilepsy
A novel drug candidate to treat temporal lobe epilepsy (TLE) has been identified, which suppresses TLE-induced neuroinflammation and curbs seizures.
TLE is one of the most common types of epilepsy. One-third of people with TLE are unresponsive to medications currently available to address symptoms, so identifying new drug targets is essential. A collaboration led by researchers at the City University of Hong Kong (China) with research institutions in Chile has identified a small organic molecule called D4 that curbs seizures and increases survival rate in a mouse model of TLE, showing promise as a drug candidate.